The Rationale and Evidence for PD-1 Checkpoint Inhibition in Advanced CSCC

The Rationale and Evidence for PD-1 Checkpoint Inhibition in Advanced CSCC

Which Patients Will Likely Benefit Most? And When Should We Initiate Treatment with PD-1-Centric Immunotherapy?


Published

March 25, 2019

Created by

CMEducation Resources symposium

Related Presenters

Todd Schlesinger, MD, FAAD

Todd Schlesinger, MD, FAAD

Director, Dermatology and Laser Center of Charleston Clinical Research Center of the Carolinas Clinical Instructor, University at Buffalo Department of Dermatology Assistant Clincal Professor, Medical University of South Carolica Department ...